Giuntoli RL 2nd - Search Results

1

Impact of delayed interval cytoreductive surgery on the survival of patients with advanced stage high-grade epithelial ovarian carcinoma.

Nasioudis D, Arevalo O, Gysler S, Ko EM, Cory L, Kim SH, Giuntoli RL 2nd, Latif NA. Nasioudis D, et al. Among authors: giuntoli rl 2nd. Int J Gynecol Cancer. 2023 Dec 6:ijgc-2023-004805. doi: 10.1136/ijgc-2023-004805. Online ahead of print. Int J Gynecol Cancer. 2023. PMID: 38088174

2

Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.

Nasioudis D, Gysler S, Latif N, Cory L, Giuntoli RL 2nd, Kim SH, Simpkins F, Martin L, Ko EM. Nasioudis D, et al. Among authors: giuntoli rl 2nd. Gynecol Oncol. 2024 Jan;180:1-5. doi: 10.1016/j.ygyno.2023.11.021. Epub 2023 Nov 28. Gynecol Oncol. 2024. PMID: 38029652

3

Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery.

Nasioudis D, Wang X, Dhillon G, Latif N, Ko EM, Giuntoli RL 2nd, Gershenson D, Fader A, Carey M, Simpkins F. Nasioudis D, et al. Among authors: giuntoli rl 2nd. Int J Gynecol Cancer. 2023 Dec 4;33(12):1906-1912. doi: 10.1136/ijgc-2023-004745. Int J Gynecol Cancer. 2023. PMID: 37879909

4

Role of immunotherapy for lymph node positive vulvar melanoma: utilization and outcomes.

Nasioudis D, Labban N, Latif N, Gysler S, Cory L, Kim S, Giuntoli RL 2nd, Ko EM. Nasioudis D, et al. Among authors: giuntoli rl 2nd. Int J Gynecol Cancer. 2023 Sep 4;33(9):1347-1353. doi: 10.1136/ijgc-2023-004696. Int J Gynecol Cancer. 2023. PMID: 37666537

5

Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma.

Nasioudis D, Latif NA, Ko EM, Cory L, Kim SH, Simpkins F, Morgan MA, Giuntoli RL 2nd. Nasioudis D, et al. Among authors: giuntoli rl 2nd. Gynecol Oncol. 2023 Feb;169:41-46. doi: 10.1016/j.ygyno.2022.10.025. Epub 2022 Dec 8. Gynecol Oncol. 2023. PMID: 36502768

6

Addition of External Beam Radiation Therapy to Adjuvant Chemotherapy for Patients With Stage IIIC Uterine Endometrioid Carcinoma: Utilization and Outcomes.

Nasioudis D, Taunk NK, Ko EM, Haggerty AF, Cory L, Giuntoli RL 2nd, Kim SH, Latif NA. Nasioudis D, et al. Among authors: giuntoli rl 2nd. Am J Clin Oncol. 2022 Sep 1;45(9):373-378. doi: 10.1097/COC.0000000000000927. Epub 2022 Aug 4. Am J Clin Oncol. 2022. PMID: 35926158

7

Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinoma.

Nasioudis D, Mastroyannis SA, Ko EM, Haggerty AF, Cory L, Giuntoli RL 2nd, Kim SH, Latif NA. Nasioudis D, et al. Among authors: giuntoli rl 2nd. Int J Gynecol Cancer. 2022 Jul 26:ijgc-2022-003450. doi: 10.1136/ijgc-2022-003450. Online ahead of print. Int J Gynecol Cancer. 2022. PMID: 35882426

8

Oncologic outcomes of surgical para-aortic lymph node staging in patients with advanced cervical carcinoma undergoing chemoradiation.

Nasioudis D, Rush M, Taunk NK, Ko EM, Haggerty AF, Cory L, Giuntoli RL 2nd, Kim SH, Latif NA. Nasioudis D, et al. Among authors: giuntoli rl 2nd. Int J Gynecol Cancer. 2022 Jul 4;32(7):823-827. doi: 10.1136/ijgc-2022-003394. Int J Gynecol Cancer. 2022. PMID: 35788115

9

Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.

Nasioudis D, Mastroyannis SA, Ko EM, Haggerty AF, Cory L, Giuntoli RL 2nd, Kim SH, Morgan MA, Latif NA. Nasioudis D, et al. Among authors: giuntoli rl 2nd. Gynecol Oncol. 2022 Aug;166(2):263-268. doi: 10.1016/j.ygyno.2022.05.015. Epub 2022 Jun 3. Gynecol Oncol. 2022. PMID: 35667901

10

Patterns of adjuvant treatment and survival outcomes in stage I uterine carcinosarcoma.

Cory L, Brensinger C, Burger RA, Giuntoli RL 2nd, Morgan MA, Latif N, Lin LL, Ko EM. Cory L, et al. Among authors: giuntoli rl 2nd. Gynecol Oncol Rep. 2022 Jan 17;39:100930. doi: 10.1016/j.gore.2022.100930. eCollection 2022 Feb. Gynecol Oncol Rep. 2022. PMID: 35111895 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

83 results

Search Page